The partnership will enable clinicians all over the world to deliver boost brachytherapy as part of the whole breast irradiation procedure, providing a superior treatment option with the ultimate goal of improving clinical outcome.
The partnership offers radiation oncology centers the opportunity to implement Advanced Radiation Therapy’s (ART) innovative technology in image-guided high-dose rate (HDR) breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron’s treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support.
ART’s expansion of AccuBoost technology through its global partnership with Nucletron is expected to further reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.
Jos Lamers, CEO of Nucletron, said: Using Nucletron’s microSelectron Digital afterloader to deliver AccuBoost technology further reduces the financial, operational, and clinical barriers many cancer centers encounter in providing brachytherapy to their patients.